Results 51 to 60 of about 21,178 (234)

Bromelain as the enzyme of the future: A global bibliometric mapping of its applications and emerging trends

Journal of the Science of Food and Agriculture, EarlyView.
Abstract INTRODUCTION Bromelain, a complex mixture of proteolytic enzymes primarily extracted from plants of the Bromeliaceae family, has gained prominence because of its broad industrial applicability, particularly in the food, pharmaceutical and cosmetic sectors.
Genésio José da Silva Neto, Tonny Cley Campos Leite, Mônica Tejo Cavalcanti, Geany Targino Sousa Pedrosa, Rerisson do Nascimento Alves, Amanda Reges de Sena, Mônica Correia Gonçalves   +6 more
wiley   +1 more source

Entero-insular axis in children with simple obesity [PDF]

Pediatric Endocrinology, Diabetes and Metabolism, 2009
Introduction: The entero-insular axis plays an important role in generation ofsatiety signal. Thus, disturbances in this axis can influence the path to a simple obesity.
Jerzy Starzyk, Krystyna Sztefko, Przemysław J. Tomasik   +2 more
doaj  

Metabolic Dysfunction‐Associated Steatotic Liver Disease and Obesity: Pathogenesis, Diagnostics, Risk Stratification, and Therapeutic Approach

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley   +1 more source

Association of Glucagon‐Like Peptide—1 Receptor Analogues and Laryngeal Symptoms in Obese Adults

The Laryngoscope, EarlyView.
Table 1 succinctly quantifies the time‑dependent association between GLP‑1RA/GIP therapy and laryngeal symptoms, demonstrating modest but statistically robust increases in outcomes such as cough and voice/resonance disorders by 6 months. It provides clinically actionable absolute risks, odds ratios, and hazard ratios that can directly inform counseling,
Priyanka Shah, David Kayekjian, Shaun A. Nguyen, Kirsten Meenan, Ashli K. O’Rourke   +4 more
wiley   +1 more source

GLP1 receptor agonists in heart failure with preserved ejection fraction (HFpEF) – beyond weight loss: a condensed scientific review

Drugs in Context
More than half of cases of heart failure (HF) now occur with preserved ejection fraction (HFpEF), a heterogeneous syndrome strongly influenced by comorbidities such as obesity, hypertension, diabetes and atrial fibrillation.
Elyzabeth Roy, Marie-Claude Parent, Anique Ducharme   +2 more
doaj   +1 more source

Gut microbiota is an endocrine organ

Ожирение и метаболизм, 2020
The gut microbiota affects the processes of food digestion, intestinal peristalsis, controls the work of the intestinal epithelium, has protective properties against pathogenic microorganisms, activating local immunity and stimulating the secretion of ...
Tatiana Y. Demidova, Kristina G. Lobanova, Olga S. Oynotkinova   +2 more
doaj   +1 more source

Endoscopic small bowel therapies for type 2 diabetes

Nutrition in Clinical Practice, EarlyView.
Abstract Type 2 diabetes is a global epidemic despite current medical treatments. Many patients are not responsive to medications, and patients with obesity are hesitant about bariatric surgery. Studies investigating the metabolic effects of Roux‐en‐Y gastric bypass have increasingly demonstrated that the duodenum plays a key role in the ...
Roma Patel, Zehra Naseem, Prisha Gattu, Stephen Firkins, Roberto Simons‐Linares   +4 more
wiley   +1 more source

Evaluating the Evolving Real‐World Adverse Events of GLP‐1RAs Using FDA Adverse Event Reporting System (FAERS)

Obesity, EarlyView.
Web portal for interrogating Adverse Events of GLP‐1 RA in diabetes vs weight control/obesity. ABSTRACT Objective This study aimed to assess the spectrum and frequency of adverse events (AEs) linked to glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) using the US FDA Adverse Event Reporting System (FAERS).
David Stone, Mary Playdon, Stephen D. Hursting, Aik Choon Tan   +3 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling More Gaps

Obesity, EarlyView.
ABSTRACT The last 2 decades have seen historic advances in the treatment of obesity. We are entering an era of defining obesity not by weight‐based outcomes but by changes in body composition. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are forming the platform for obesity treatments based on their high level of efficacy. Body composition can
Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway   +4 more
wiley   +1 more source

Gastric inhibitory polypeptide links overnutrition to obesity [PDF]

Gut, 2003
A gut derived peptide, gastric inhibitory polypeptide, directly links overnutrition to obesity and may be a potential target for antiobesity drugs Obesity and diabetes are two of the most prevalent health conditions in industrial nations. Recent studies suggest that a gut derived peptide, gastric inhibitory polypeptide (GIP), may be involved in the ...
openaire   +2 more sources